SAN DIEGO, May 12, 2015 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that it will host
an Analyst and Investor Day at the New York Palace Hotel in
New York City on Thursday May 21, 2015 from 12:00 p.m. to 3:30 p.m. ET (9:00 a.m. to 12:30 p.m. PT).
Presenters will include:
- Kevin Gorman, President and
Chief Executive Officer
- Timothy Coughlin, Chief
Financial Officer
- Christopher O'Brien, Chief
Medical Officer
- Kyle Gano, Chief Business
Development Officer
- Dimitri Grigoriadis, Chief
Research Officer
- Sylvia Hannaman, Director of
Market Research and Planning
- Dr. Bruce Carr, MD, Professor of
Obstetrics and Gynecology at UT Southwestern Medical Center
- Dr. Stewart Factor, Professor of
Neurology Director, Emory Comprehensive Parkinson's Disease Center
and the Movement Disorders Program
- Dr. Karen Lin Su, Medical
Director Cares Foundation
To attend the live event at the New York Palace Hotel, please
contact Neurocrine investor relations at ir@neurocrine.com.
To access the webcast on May 21,
go to the homepage on www.neurocrine.com and click on the Webcasts
& Presentations box to access the link. Listeners are
encouraged to visit the website approximately 5 minutes prior to
the presentation to download or install any necessary
software. A replay of the presentation will be available on
the website approximately one hour after the conclusion of the
event and will be archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine
transporter 2 inhibitor for the treatment of movement
disorders. Neurocrine intends to maintain certain commercial
rights to its VMAT2 inhibitor for evolution into a fully-integrated
pharmaceutical company. Neurocrine Biosciences, Inc. news
releases are available through the Company's website via the
internet at http://www.neurocrine.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-host-analyst-and-investor-day-in-new-york-city-on-may-21-2015-300082056.html
SOURCE Neurocrine Biosciences, Inc.